Study calls for more research on health data exchange

More thorough studies are needed to determine the effect health data exchange has on clinical outcomes, according to a study published in the Journal of Medical Internet Research.

For the study, researchers from Oregon Health & Science University, the University of Washington-Seattle and the Department of Veterans Affairs' Maine Healthcare System reviewed studies of health data exchange in clinical or public health settings with publication dates between January 1990 and February 2015.

The researchers identified 34 studies that looked at health data exchange outcomes and noted that most of the studies were "retrospective cohorts," where the exchanges focused on one specific outcome; or surveys that examined perceived outcomes.

The studies did not include findings on clinical outcomes, such as mortality or morbidity, or potential issues caused by health data exchange.

That evidence is "low quality" because the studies were retrospective and limited in the scope of their questioning, according to the authors. "None of the studies analyzed individual episodes of care to determine clinical appropriateness of possible changes brought about by [health data exchange] use," they wrote.

The researchers recommended that future studies: adopt a standard for describing types of health data exchange; ask more comprehensive questions; and be more rigorously designed.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.